{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:25:52Z","timestamp":1790814352708,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06630-5","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:44:42Z","timestamp":1760949882000},"page":"5881-5889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic potential of albumin to fibrinogen ratio in multiple myeloma patients"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5641-2974","authenticated-orcid":false,"given":"Melania","family":"Carlisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7491-568X","authenticated-orcid":false,"given":"Rosalia Lo","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3686-2214","authenticated-orcid":false,"given":"Angelo","family":"Pirrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0755-231X","authenticated-orcid":false,"given":"Antonino Elia","family":"Augello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-6508","authenticated-orcid":false,"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8964-255X","authenticated-orcid":false,"given":"Gregorio","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"issue":"6","key":"6630_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"key":"6630_CR2","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.2147\/CMAR.S198419","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Xiao G (2019) Prognostic significance of the ratio of fibrinogen and albumin in human malignancies: a meta-analysis. Cancer Manag Res 11:3381\u20133393. https:\/\/doi.org\/10.2147\/CMAR.S198419","journal-title":"Cancer Manag Res"},{"issue":"1","key":"6630_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-1786-2","volume":"18","author":"DW Sun","year":"2020","unstructured":"Sun DW, An L, Lv GY (2020) Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis. World J Surg Oncol 18(1):9. https:\/\/doi.org\/10.1186\/s12957-020-1786-2","journal-title":"World J Surg Oncol"},{"issue":"9","key":"6630_CR4","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1007\/s00405-022-07391-x","volume":"279","author":"S Wang","year":"2022","unstructured":"Wang S, Feng Y, Xie Y, Zhao X, Ma J, Liu X, Hu C, Hou T (2022) High fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection. Eur Arch Otorhinolaryngol 279(9):4541\u20134548. https:\/\/doi.org\/10.1007\/s00405-022-07391-x","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5","key":"6630_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4149\/neo_2022_220422N441","volume":"69","author":"H Zhu","year":"2022","unstructured":"Zhu H, Zhang W, Ye P, Wu M (2022) Preoperative circulating fibrinogen to albumin ratio in predicting 5-year prognosis of oral cancer radical surgery. Neoplasma 69(5):1246\u20131252. https:\/\/doi.org\/10.4149\/neo_2022_220422N441","journal-title":"Neoplasma"},{"issue":"8","key":"6630_CR6","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1080\/01635581.2022.2042572","volume":"74","author":"H Xie","year":"2022","unstructured":"Xie H, Yuan G, Liu M, Huang S, Wei L, Tang S, Gan J (2022) Pretreatment albumin-to-fibrinogen ratio is a promising biomarker for predicting postoperative clinical outcomes in patients with colorectal cancer. Nutr Cancer 74(8):2896\u20132909. https:\/\/doi.org\/10.1080\/01635581.2022.2042572","journal-title":"Nutr Cancer"},{"issue":"10","key":"6630_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58101490","volume":"58","author":"B Barone","year":"2022","unstructured":"Barone B, Napolitano L, Reccia P, De Luca L, Morra S, Turco C, Melchionna A, Caputo VF, Cirillo L, Fusco GM, Mastrangelo F, Calace FP, Amicuzi U, Morgera V, Romano L, Trivellato M, Mattiello G, Sicignano E, Passaro F, Ferretti G, Giampaglia G, Capone F, Manfredi C, Crocetto F (2022) Preoperative fibrinogen-to-albumin ratio as potential predictor of bladder cancer: a monocentric retrospective study. Medicina (B Aires) 58(10):1490. https:\/\/doi.org\/10.3390\/medicina58101490","journal-title":"Medicina (B Aires)"},{"issue":"1","key":"6630_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12894-022-01118-0","volume":"22","author":"O Demir","year":"2022","unstructured":"Demir O, Demirag G, Aslan G (2022) Prospective evaluation of hematological parameters in preoperative renal cell cancer patients. BMC Urol 22(1):201. https:\/\/doi.org\/10.1186\/s12894-022-01118-0","journal-title":"BMC Urol"},{"issue":"36","key":"6630_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034926","volume":"102","author":"Y Fu","year":"2023","unstructured":"Fu Y, Yu Y, Zhou Y, Li T, Xie Y, Wang Y, Ran Q, Chen Y, Fan X (2023) The fibrinogen-albumin ratio as a novel prognostic factor for elderly patients with osteosarcoma. Medicine 102(36):e34926. https:\/\/doi.org\/10.1097\/MD.0000000000034926","journal-title":"Medicine"},{"issue":"20","key":"6630_CR10","doi-asserted-by":"publisher","first-page":"20321","DOI":"10.1002\/cam4.6606","volume":"12","author":"F Li","year":"2023","unstructured":"Li F, Ren Y, Fan J, Zhou J (2023) The predictive value of the preoperative albumin-to-fibrinogen ratio for postoperative hospital length of stay in liver cancer patients. Cancer Med 12(20):20321\u201320331. https:\/\/doi.org\/10.1002\/cam4.6606","journal-title":"Cancer Med"},{"issue":"1","key":"6630_CR11","doi-asserted-by":"publisher","first-page":"20630","DOI":"10.1038\/s41598-023-48029-0","volume":"13","author":"C Deng","year":"2023","unstructured":"Deng C, Zhang S, Ling J, Chen Z, Feng Y, Xie Y, Liu X, Hu C, Hou T (2023) Prognostic value of the fibrinogen albumin ratio index (FARI) in nasopharyngeal carcinoma patients undergoing radiotherapy. Sci Rep 13(1):20630. https:\/\/doi.org\/10.1038\/s41598-023-48029-0","journal-title":"Sci Rep"},{"issue":"8","key":"6630_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/1354750X.2023.2281870","volume":"28","author":"X Zhang","year":"2023","unstructured":"Zhang X, Qiu X, Yin H, Zhao W, Song L, Zhang X, Yang L, Tao M (2023) The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy. Biomarkers 28(8):714\u2013721. https:\/\/doi.org\/10.1080\/1354750X.2023.2281870","journal-title":"Biomarkers"},{"issue":"3","key":"6630_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037031","volume":"103","author":"K Li","year":"2024","unstructured":"Li K, Yan J, Zhang H, Lu C, Wang W, Guo M, Zhang X, Zhang Z (2024) Prognostic value of preoperative white blood cell to hemoglobin ratio and fibrinogen to albumin ratio in patients with colorectal cancer. Medicine 103(3):e37031. https:\/\/doi.org\/10.1097\/MD.0000000000037031","journal-title":"Medicine"},{"issue":"2","key":"6630_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.4143\/crt.2018.358","volume":"51","author":"YX Zou","year":"2019","unstructured":"Zou YX, Qiao J, Zhu HY, Lu RN, Xia Y, Cao L, Wu W, Jin H, Liu WJ, Liang JH, Wu JZ, Wang L, Fan L, Xu W, Li JY (2019) Albumin-to-fibrinogen ratio as an independent prognostic parameter in untreated chronic lymphocytic leukemia: a retrospective study of 191 cases. Cancer Res Treat 51(2):664\u2013671. https:\/\/doi.org\/10.4143\/crt.2018.358","journal-title":"Cancer Res Treat"},{"issue":"4","key":"6630_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00277-021-04440-z","volume":"100","author":"M Akimoto","year":"2021","unstructured":"Akimoto M, Sakurai A, Nishiyama-Fujita Y, Ito C, Aisa Y, Nakazato T (2021) The prognostic value of the Fibrinogen-Albumin ratio index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with Azacitidine. Ann Hematol 100(4):953\u2013957. https:\/\/doi.org\/10.1007\/s00277-021-04440-z","journal-title":"Ann Hematol"},{"issue":"3","key":"6630_CR16","doi-asserted-by":"publisher","first-page":"762","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.03.021","volume":"31","author":"H Deng","year":"2023","unstructured":"Deng H, Zhang L, Wang HY, Huang MJ, Wei J, Zou XL (2023) [Prognostic value of Pre-treatment albumin\/fibrinogen ratio in patients with diffuse large B-cell lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 31(3):762\u2013768 Chinese. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2023.03.021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"6630_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3228","volume":"42","author":"T Sakuma","year":"2024","unstructured":"Sakuma T, Fujisawa S, Tanaka M, Hagihara M, Fujita H, Fujimaki K, Katsuki K, Akimoto M, Tanaka M, Matsumura A, Teshigawara H, Suzuki T, Teranaka H, Nakajima Y, Miyazaki T, Tachibana T, Matsumoto K, Sakai R, Kanamori H, Nakajima H (2024) Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: a multicenter retrospective study. Hematol Oncol 42(1):e3228. https:\/\/doi.org\/10.1002\/hon.3228","journal-title":"Hematol Oncol"},{"issue":"11","key":"6630_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ajh.23303","volume":"87","author":"RS Komrokji","year":"2012","unstructured":"Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF (2012) Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol 87(11):1006\u20131009. https:\/\/doi.org\/10.1002\/ajh.23303","journal-title":"Am J Hematol"},{"issue":"3","key":"6630_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/10428194.2019.1686499","volume":"61","author":"N Wang","year":"2020","unstructured":"Wang N, Desai A, Ge B, Li W, Jin X, Bai H, Yu K, Ye H (2020) Prognostic value of hypoalbuminemia at diagnosis in de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 61(3):641\u2013649. https:\/\/doi.org\/10.1080\/10428194.2019.1686499","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6630_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/hon.2925","volume":"39","author":"K Doucette","year":"2021","unstructured":"Doucette K, Percival ME, Williams L, Kandahari A, Taylor A, Wang S, Ahn J, Karp JE, Lai C (2021) Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia. Hematol Oncol 39(5):697\u2013706. https:\/\/doi.org\/10.1002\/hon.2925","journal-title":"Hematol Oncol"},{"issue":"6","key":"6630_CR21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.21037\/tcr-23-503","volume":"12","author":"X Hu","year":"2023","unstructured":"Hu X, Feng X, Wang H, Miao Y, Lian X, Gao Q, Gao Y, Zhai X, Zhang D, Niu B, Wang Y (2023) Association between serum albumin levels and survival in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective study. Transl Cancer Res 12(6):1577\u20131587. https:\/\/doi.org\/10.21037\/tcr-23-503","journal-title":"Transl Cancer Res"},{"issue":"10","key":"6630_CR22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ctrv.2015.10.002","volume":"41","author":"C Perisanidis","year":"2015","unstructured":"Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, Stift A, Filipits M, Kornek G, Nkenke E (2015) Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev 41(10):960\u2013970. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.002","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"6630_CR23","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1182\/blood.V96.10.3302","volume":"96","author":"JS Palumbo","year":"2000","unstructured":"Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96(10):3302\u20133309","journal-title":"Blood"},{"issue":"2","key":"6630_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2019.236901","volume":"105","author":"R Vilar","year":"2020","unstructured":"Vilar R, Fish RJ, Casini A, Neerman-Arbez M (2020) Fibrin(ogen) in human disease: both friend and foe. Haematologica 105(2):284\u2013296. https:\/\/doi.org\/10.3324\/haematol.2019.236901","journal-title":"Haematologica"},{"issue":"4","key":"6630_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/jclinpath-2015-203356","volume":"69","author":"KT Troppan","year":"2016","unstructured":"Troppan KT, Melchardt T, Wenzl K, Schlick K, Deutsch A, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Tr\u00e4nkenschuh W, Greil R, Neumeister P, Egle A, Pichler M (2016) The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. J Clin Pathol 69(4):326\u2013330. https:\/\/doi.org\/10.1136\/jclinpath-2015-203356","journal-title":"J Clin Pathol"},{"issue":"10","key":"6630_CR26","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00277-018-3382-x","volume":"97","author":"JY Niu","year":"2018","unstructured":"Niu JY, Tian T, Zhu HY, Liang JH, Wu W, Cao L, Lu RN, Wang L, Li JY, Xu W (2018) Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma. Ann Hematol 97(10):1841\u20131849. https:\/\/doi.org\/10.1007\/s00277-018-3382-x","journal-title":"Ann Hematol"},{"issue":"1","key":"6630_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00277-019-03863-z","volume":"99","author":"S Ogura","year":"2020","unstructured":"Ogura S, Yonei S, Tanigawa T, Akimoto M, Sakurai A, Fujita Y, Ito C, Aisa Y, Nakazato T (2020) Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes. Ann Hematol 99(1):189\u2013191. https:\/\/doi.org\/10.1007\/s00277-019-03863-z","journal-title":"Ann Hematol"},{"key":"6630_CR28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/CMAR.S363568","volume":"14","author":"C Shi","year":"2022","unstructured":"Shi C, Gong S, Wu A, Niu T, Wu N, Zhang Y, Ouyang G, Mu Q (2022) Hyperfibrinogenemia as a poor prognostic indicator in myelodysplastic syndrome. Cancer Manag Res 14:1857\u20131865. https:\/\/doi.org\/10.2147\/CMAR.S363568","journal-title":"Cancer Manag Res"},{"issue":"4","key":"6630_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/hon.2307","volume":"35","author":"MD Berger","year":"2017","unstructured":"Berger MD, Heini AD, Seipel K, Mueller B, Angelillo-Scherrer A, Pabst T (2017) Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia. Hematol Oncol 35(4):789\u2013796. https:\/\/doi.org\/10.1002\/hon.2307","journal-title":"Hematol Oncol"},{"issue":"6","key":"6630_CR30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/10428194.2018.1535116","volume":"60","author":"K Dai","year":"2019","unstructured":"Dai K, Zhang Q, Li Y, Wu L, Zhang S, Yu K (2019) Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia. Leuk Lymphoma 60(6):1503\u20131511. https:\/\/doi.org\/10.1080\/10428194.2018.1535116","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"6630_CR31","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1080\/10428194.2020.1780587","volume":"61","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang R, Qi J, Miao W, Fang K, Ruan C, Wu D, Han Y (2020) The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis. Leuk Lymphoma 61(11):2682\u20132691. https:\/\/doi.org\/10.1080\/10428194.2020.1780587","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6630_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/biomedicines11030964","volume":"11","author":"M Carlisi","year":"2023","unstructured":"Carlisi M, Lo Presti R, Mancuso S, Siragusa S, Caimi G (2023) Calculated whole blood viscosity and albumin\/fibrinogen ratio in patients with a new diagnosis of multiple myeloma: relationships with some prognostic predictors. Biomedicines 11(3):964. https:\/\/doi.org\/10.3390\/biomedicines11030964","journal-title":"Biomedicines"},{"key":"6630_CR33","first-page":"14","volume":"8","author":"L Dintenfass","year":"1979","unstructured":"Dintenfass L (1979) Haemorheology of diabetes mellitus. Adv Microcirc (Microcirculation Diabetes) 8:14\u201336","journal-title":"Adv Microcirc (Microcirculation Diabetes)"},{"key":"6630_CR34","volume-title":"Blood viscosity. Hyperviscosity & hyperviscosemia","author":"L Dintenfass","year":"1985","unstructured":"Dintenfass L (1985) Blood viscosity. Hyperviscosity & hyperviscosemia. MTP Press Limited, Falcon House Lancaster"},{"issue":"25","key":"6630_CR35","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1182\/blood.2021011285","volume":"138","author":"A Caulier","year":"2021","unstructured":"Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, Hulin C, Perrot A, Richez V, Michaud AV, Touzeau C, Doyen C, Mariette C, Caillot D, Harel S, Lenain P, Ivanoff S, Fontan J, Stoppa AM, Manier S, Garderet L, Leleu X, Marolleau JP, Arnulf B, Avet-Loiseau H, Royer B (2021) Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood 138(25):2686\u20132695. https:\/\/doi.org\/10.1182\/blood.2021011285","journal-title":"Blood"},{"key":"6630_CR36","doi-asserted-by":"publisher","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Davies FE, Morgan GJ (2011) Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 20(8):1703-7. https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0157","DOI":"10.1158\/1055-9965.EPI-11-0157"},{"key":"6630_CR37","doi-asserted-by":"publisher","unstructured":"Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BC (2021) Sex differences in outcomes in multiple myeloma. Br J Haematol 192(3):e66-e69. https:\/\/doi.org\/10.1111\/bjh.17237","DOI":"10.1111\/bjh.17237"},{"issue":"3","key":"6630_CR38","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1111\/bjh.17237","volume":"192","author":"BA Derman","year":"2021","unstructured":"Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BC (2021) Sex differences in outcomes in multiple myeloma. Br J Haematol 192(3):e66\u2013e69. https:\/\/doi.org\/10.1111\/bjh.17237","journal-title":"Br J Haematol"},{"issue":"10","key":"6630_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clml.2021.04.013","volume":"21","author":"S Bird","year":"2021","unstructured":"Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G, Drayson M, Gregory W, Jenner M, Jones J, Kaiser M, Owen R, Jackson G, Morgan G, Pawlyn C (2021) Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the myeloma XI trial. Clin Lymphoma Myeloma Leuk 21(10):667\u2013675. https:\/\/doi.org\/10.1016\/j.clml.2021.04.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"6630_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000525493","volume":"45","author":"A Brioli","year":"2022","unstructured":"Brioli A, N\u00e4gler TM, Yomade O, R\u00fcthrich MM, Scholl S, Frietsch JJ, Hilgendorf I, Ernst T, Sayer HG, Hochhaus A, M\u00fcgge LO, von Lilienfeld-Toal M (2022) Sex-disaggregated analysis of biology, treatment tolerability, and outcome of multiple myeloma in a German cohort. Oncol Res Treat 45(9):494\u2013503. https:\/\/doi.org\/10.1159\/000525493","journal-title":"Oncol Res Treat"},{"issue":"6","key":"6630_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5301\/ejo.5000942","volume":"27","author":"H Guclu","year":"2017","unstructured":"Guclu H, Ozal SA, Pelitli Gurlu V, \u00d6zg\u00fcn GS, \u00d6zg\u00fcn E (2017) Increased fibrinogen to albumin ratio in ischemic retinal vein occlusions. Eur J Ophthalmol 27(6):735\u2013739. https:\/\/doi.org\/10.5301\/ejo.5000942","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"6630_CR42","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s13760-023-02294-y","volume":"123","author":"F \u015eim\u015fek","year":"2023","unstructured":"\u015eim\u015fek F, Yevgi R (2023) Assessment of fibrinogen albumin ratio in patients with pregnancy-related cerebral venous thrombosis. Acta Neurol Belg 123(6):2251\u20132258. https:\/\/doi.org\/10.1007\/s13760-023-02294-y","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"6630_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1160\/TH09-12-0856","volume":"104","author":"AR Folsom","year":"2010","unstructured":"Folsom AR, Lutsey PL, Heckbert SR, Cushman M (2010) Serum albumin and risk of venous thromboembolism. Thromb Haemost 104(1):100\u2013104. https:\/\/doi.org\/10.1160\/TH09-12-0856","journal-title":"Thromb Haemost"},{"issue":"1","key":"6630_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ajh.25296","volume":"94","author":"G Chi","year":"2019","unstructured":"Chi G, Gibson CM, Liu Y, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ (2019) Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: analysis from the APEX trial. Am J Hematol 94(1):21\u201328. https:\/\/doi.org\/10.1002\/ajh.25296","journal-title":"Am J Hematol"},{"key":"6630_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231178547","volume":"29","author":"X Xiong","year":"2023","unstructured":"Xiong X, Li T, Yu S, Lu X, Mao Q, Xiong Y (2023) Association between low serum albumin and preoperative deep vein thrombosis in patients undergoing total joint arthroplasty: a retrospective study. Clin Appl Thromb Hemost 29:10760296231178547. https:\/\/doi.org\/10.1177\/10760296231178547","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3 Suppl 8","key":"6630_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/sonc.2002.33532","volume":"29","author":"T Littlewood","year":"2002","unstructured":"Littlewood T, Mandelli F (2002) The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 29(3 Suppl 8):40\u201344. https:\/\/doi.org\/10.1053\/sonc.2002.33532","journal-title":"Semin Oncol"},{"issue":"2","key":"6630_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF02983379","volume":"78","author":"F Silvestris","year":"2003","unstructured":"Silvestris F, Tucci M, Quatraro C, Dammacco F (2003) Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol 78(2):121\u2013125. https:\/\/doi.org\/10.1007\/BF02983379","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"6630_CR48","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.3816\/clm.2003.s.005","volume":"4","author":"M Mittelman","year":"2003","unstructured":"Mittelman M (2003) The implications of anemia in multiple myeloma. Clin Lymphoma 4(Suppl 1):S23\u2013S29. https:\/\/doi.org\/10.3816\/clm.2003.s.005","journal-title":"Clin Lymphoma"},{"issue":"4","key":"6630_CR49","first-page":"233","volume":"2","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2(4):233\u2013241","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"6630_CR50","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24291","volume":"91","author":"A Bouchnita","year":"2016","unstructured":"Bouchnita A, Eymard N, Moyo TK, Koury MJ, Volpert V (2016) Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Am J Hematol 91(4):371\u2013378. https:\/\/doi.org\/10.1002\/ajh.24291","journal-title":"Am J Hematol"},{"issue":"2","key":"6630_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.mehy.2005.08.041","volume":"66","author":"A Cucuianu","year":"2006","unstructured":"Cucuianu A, Patiu M, Rusu A (2006) Hepcidin and multiple myeloma related anemia. Med Hypotheses 66(2):352\u2013354. https:\/\/doi.org\/10.1016\/j.mehy.2005.08.041","journal-title":"Med Hypotheses"},{"issue":"11","key":"6630_CR52","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-07-4153","volume":"14","author":"S Sharma","year":"2008","unstructured":"Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, Ganz T, Lichtenstein A (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14(11):3262\u20133267. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4153","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6630_CR53","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s12185-014-1626-7","volume":"100","author":"S Mei","year":"2014","unstructured":"Mei S, Wang H, Fu R, Qu W, Xing L, Wang G, Song J, Liu H, Li L, Wang X, Wu Y, Guan J, Ruan E, Shao Z (2014) Hepcidin and GDF15 in anemia of multiple myeloma. Int J Hematol 100(3):266\u2013273. https:\/\/doi.org\/10.1007\/s12185-014-1626-7","journal-title":"Int J Hematol"},{"issue":"6","key":"6630_CR54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.5455\/medarh.2016.70.429-432","volume":"70","author":"L Ibricevic-Balic","year":"2016","unstructured":"Ibricevic-Balic L, Icindic-Nakas E, Hasic S, Kiseljakovic E, Sofo-Hafizovic A, Balic S (2016) Dilemma: correlation between serum level of Hepcidin and IL-6 in anemic myeloma patients. Med Arch 70(6):429\u2013432. https:\/\/doi.org\/10.5455\/medarh.2016.70.429-432","journal-title":"Med Arch"},{"issue":"7","key":"6630_CR55","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.7754\/Clin.Lab.2017.160637","volume":"63","author":"M Victor","year":"2017","unstructured":"Victor M, Evgeniy H, Gergana T, Julia P, Vasil V, Borislav M, Ivo B, Zlatina G, Kamen T (2017) Serum hepcidin levels in multiple myeloma. Clin Lab 63(7):1273\u20131277. https:\/\/doi.org\/10.7754\/Clin.Lab.2017.160637","journal-title":"Clin Lab"},{"issue":"3","key":"6630_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58030417","volume":"58","author":"M Banaszkiewicz","year":"2022","unstructured":"Banaszkiewicz M, Ma\u0142yszko J, Batko K, Koc-\u017b\u00f3rawska E, \u017b\u00f3rawski M, Dumnicka P, Jurczyszyn A, Woziwodzka K, Maleszka A, Krzanowski M, Kra\u015bniak A, Dro\u017cd\u017c R, Krzanowska K (2022) The key role of Hepcidin-25 in anemia in multiple myeloma patients with renal impairment. Medicina (Kaunas) 58(3):417. https:\/\/doi.org\/10.3390\/medicina58030417","journal-title":"Medicina (Kaunas)"},{"issue":"18","key":"6630_CR57","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2010-03-274571","volume":"116","author":"K Maes","year":"2010","unstructured":"Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S, Vanderkerken K, Lichtenstein A, Ganz T (2010) In anemia of multiple myeloma, Hepcidin is induced by increased bone morphogenetic protein 2. Blood 116(18):3635\u20133644. https:\/\/doi.org\/10.1182\/blood-2010-03-274571","journal-title":"Blood"},{"issue":"2","key":"6630_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/10428194.2013.804521","volume":"55","author":"A Lichtenstein","year":"2014","unstructured":"Lichtenstein A (2014) Anemia in lymphoma: interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma 55(2):231\u2013232. https:\/\/doi.org\/10.3109\/10428194.2013.804521","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"6630_CR59","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/cncr.24959","volume":"116","author":"D Rossi","year":"2010","unstructured":"Rossi D, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G, Gaidano G (2010) Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer 116(9):2188\u20132200. https:\/\/doi.org\/10.1002\/cncr.24959","journal-title":"Cancer"},{"issue":"5","key":"6630_CR60","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ejh.13356","volume":"104","author":"V Pfahler","year":"2020","unstructured":"Pfahler V, D\u2019Anastasi M, D\u00fcrr HR, Schinner R, Ricke J, Baur-Melnyk A (2020) Tumor load in patients with multiple myeloma: \u03b2\u2082-microglobulin levels versus low-dose whole-body CT. Eur J Haematol 104(5):383\u2013389. https:\/\/doi.org\/10.1111\/ejh.13356","journal-title":"Eur J Haematol"},{"issue":"1","key":"6630_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/jcrt.JCRT_666_16","volume":"16","author":"A Maaroufi","year":"2020","unstructured":"Maaroufi A, Khadem-Ansari MH, Khalkhali HR, Rasmi Y (2020) Serum levels of bone sialoprotein, osteopontin, and \u03b22-microglobulin in stage I of multiple myeloma. J Cancer Res Ther 16(1):98\u2013101. https:\/\/doi.org\/10.4103\/jcrt.JCRT_666_16","journal-title":"J Cancer Res Ther"},{"key":"6630_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1322680","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Lin Z, Zheng Z, Wang Q, Zhou S, Zhang B, Zheng D, Chen Z, Zheng S, Zhang Y, Lin X, Dong R, Chen J, Qian H, Hu X, Zhuang Y, Zhang Q, Jin Z, Jiang S, Ma Y (2024) Prognostic significance of \u03b22-microglobulin decline index in multiple myeloma. Front Oncol 14:1322680. https:\/\/doi.org\/10.3389\/fonc.2024.1322680","journal-title":"Front Oncol"},{"key":"6630_CR63","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/145619","volume":"2014","author":"H Lee","year":"2014","unstructured":"Lee H, Kong SY, Sohn JY, Shim H, Youn HS, Lee S, Kim HJ, Eom HS (2014) Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. Biomed Res Int 2014:145619. https:\/\/doi.org\/10.1155\/2014\/145619","journal-title":"Biomed Res Int"},{"issue":"3","key":"6630_CR64","first-page":"282","volume":"47","author":"S Meng","year":"2017","unstructured":"Meng S, Ma Z, Lu C, Liu H, Tu H, Zhang W, Zhou F (2017) Prognostic value of elevated red blood cell distribution width in Chinese patients with multiple myeloma. Ann Clin Lab Sci 47(3):282\u2013290","journal-title":"Ann Clin Lab Sci"},{"key":"6630_CR65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cca.2018.02.009","volume":"481","author":"D Zhou","year":"2018","unstructured":"Zhou D, Xu P, Peng M, Shao X, Wang M, Ouyang J, Chen B (2018) Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. Clin Chim Acta 481:34\u201341. https:\/\/doi.org\/10.1016\/j.cca.2018.02.009","journal-title":"Clin Chim Acta"},{"issue":"1","key":"6630_CR66","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1186\/s12885-018-5086-y","volume":"18","author":"L Ai","year":"2018","unstructured":"Ai L, Mu S, Wang Y, Wang H, Cai L, Li W, Hu Y (2018) Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis. BMC Cancer 18(1):1220. https:\/\/doi.org\/10.1186\/s12885-018-5086-y","journal-title":"BMC Cancer"},{"issue":"1","key":"6630_CR67","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12885-022-09902-9","volume":"22","author":"X Chen","year":"2022","unstructured":"Chen X, Liu J, Duan J, Xiong H, Liu Y, Zhang X, Huang C (2022) Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis. BMC Cancer 22(1):796. https:\/\/doi.org\/10.1186\/s12885-022-09902-9","journal-title":"BMC Cancer"},{"key":"6630_CR68","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.2147\/IJGM.S328035","volume":"14","author":"J Long","year":"2021","unstructured":"Long J, Xie X, Xu D, Huang C, Liu Y, Meng X, Cai X, Fang X (2021) Association between red blood cell distribution width-to-albumin ratio and prognosis of patients with aortic aneurysms. Int J Gen Med 14:6287\u20136294. https:\/\/doi.org\/10.2147\/IJGM.S328035","journal-title":"Int J Gen Med"},{"key":"6630_CR69","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3979213","volume":"2022","author":"P Liu","year":"2022","unstructured":"Liu P, Luo S, Duan XJ, Chen X, Zhou Q, Jiang Y, Liu X (2022) RDW-to-ALB ratio is an independent predictor for 30-day all-cause mortality in patients with acute ischemic stroke: a retrospective analysis from the MIMIC-IV database. Behav Neurol 2022:3979213. https:\/\/doi.org\/10.1155\/2022\/3979213","journal-title":"Behav Neurol"},{"issue":"1","key":"6630_CR70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-022-01534-4","volume":"21","author":"J Hong","year":"2022","unstructured":"Hong J, Hu X, Liu W, Qian X, Jiang F, Xu Z, Shen F, Zhu H (2022) Impact of red cell distribution width and red cell distribution width\/albumin ratio on all-cause mortality in patients with type 2 diabetes and foot ulcers: a retrospective cohort study. Cardiovasc Diabetol 21(1):91. https:\/\/doi.org\/10.1186\/s12933-022-01534-4","journal-title":"Cardiovasc Diabetol"},{"key":"6630_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cca.2021.12.027","volume":"527","author":"Q Ni","year":"2022","unstructured":"Ni Q, Wang X, Wang J, Chen P (2022) The red blood cell distribution width-albumin ratio: a promising predictor of mortality in heart failure patients - a cohort study. Clin Chim Acta 527:38\u201346. https:\/\/doi.org\/10.1016\/j.cca.2021.12.027","journal-title":"Clin Chim Acta"},{"key":"6630_CR72","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221121286","volume":"28","author":"D Li","year":"2022","unstructured":"Li D, Ruan Z, Wu B (2022) Association of red blood cell distribution width-albumin ratio for acute myocardial infarction patients with mortality: a retrospective cohort study. Clin Appl Thromb Hemost 28:10760296221121286. https:\/\/doi.org\/10.1177\/10760296221121286","journal-title":"Clin Appl Thromb Hemost"},{"key":"6630_CR73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/NDT.S350588","volume":"18","author":"Z Qin","year":"2022","unstructured":"Qin Z, Liao N, Lu X, Duan X, Zhou Q, Ge L (2022) Relationship between the hemoglobin-to-red cell distribution width ratio and all-cause mortality in ischemic stroke patients with atrial fibrillation: an analysis from the MIMIC-IV database. Neuropsychiatr Dis Treat 18:341\u2013354. https:\/\/doi.org\/10.2147\/NDT.S350588","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"6630_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030886","volume":"11","author":"E Rahamim","year":"2022","unstructured":"Rahamim E, Zwas DR, Keren A, Elbaz-Greener G, Ibrahimli M, Amir O, Gotsman I (2022) The ratio of hemoglobin to red cell distribution width: a strong predictor of clinical outcome in patients with heart failure. J Clin Med 11(3):886. https:\/\/doi.org\/10.3390\/jcm11030886","journal-title":"J Clin Med"},{"key":"6630_CR75","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/IJGM.S393393","volume":"16","author":"L Jian","year":"2023","unstructured":"Jian L, Zhang Z, Zhou Q, Duan X, Ge L (2023) Red cell distribution width\/albumin ratio: a predictor of in-hospital all-cause mortality in patients with acute myocardial infarction in the ICU. Int J Gen Med 16:745\u2013756. https:\/\/doi.org\/10.2147\/IJGM.S393393","journal-title":"Int J Gen Med"},{"issue":"3","key":"6630_CR76","doi-asserted-by":"publisher","first-page":"765","DOI":"10.19746\/j.cnki.issn.1009-2137.2022.03.017","volume":"30","author":"XY Dong","year":"2022","unstructured":"Dong XY, Tang GF, Chen W, Cao J, Cheng H, Li ZY, Xu KL (2022) [Influence of the ratio of peripheral Hemoglobin-to-Red cell distribution width on the prognosis of patients with diffuse large B-cell lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30(3):765\u2013770 Chinese. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2022.03.017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"6","key":"6630_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2217\/bmm-2021-0577","volume":"16","author":"G Chi","year":"2022","unstructured":"Chi G, Lee JJ, Montazerin SM, Marszalek J (2022) Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis. Biomark Med 16(6):473\u2013482. https:\/\/doi.org\/10.2217\/bmm-2021-0577","journal-title":"Biomark Med"},{"issue":"12","key":"6630_CR78","doi-asserted-by":"publisher","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","volume":"115","author":"MA Dimopoulos","year":"1991","unstructured":"Dimopoulos MA, Barlogie B, Smith TL, Alexanian R (1991) High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115(12):931\u2013935. https:\/\/doi.org\/10.7326\/0003-4819-115-12-931","journal-title":"Ann Intern Med"},{"issue":"2","key":"6630_CR79","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","volume":"85","author":"E Terpos","year":"2010","unstructured":"Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA (2010) High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 85(2):114\u2013119. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01466.x","journal-title":"Eur J Haematol"},{"issue":"29","key":"6630_CR80","doi-asserted-by":"publisher","first-page":"48350","DOI":"10.18632\/oncotarget.16237","volume":"8","author":"Y Gu","year":"2017","unstructured":"Gu Y, Yuan YH, Xu J, Shi QL, Qu XY, Guo R, Bai H, Xu JD, Li JY, Chen LJ (2017) High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. Oncotarget 8(29):48350\u201348361. https:\/\/doi.org\/10.18632\/oncotarget.16237","journal-title":"Oncotarget"},{"issue":"6","key":"6630_CR81","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000506174","volume":"143","author":"H Lee","year":"2020","unstructured":"Lee H, Jimenez-Zepeda VH (2020) The prognostic role of lactate dehydrogenase at first relapse of multiple myeloma. Acta Haematol 143(6):516\u2013517. https:\/\/doi.org\/10.1159\/000506174","journal-title":"Acta Haematol"},{"issue":"6","key":"6630_CR82","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1159\/000505737","volume":"143","author":"Y Liu","year":"2020","unstructured":"Liu Y, Wen L, Chen H, Chen Y, Duan W, Kang Y, Ma L, Huang X, Lu J (2020) Serum lactate dehydrogenase can be used as a factor for re-evaluating first-relapsed multiple myeloma. Acta Haematol 143(6):559\u2013566. https:\/\/doi.org\/10.1159\/000505737","journal-title":"Acta Haematol"},{"issue":"2","key":"6630_CR83","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/hon.2955","volume":"40","author":"Y Shang","year":"2022","unstructured":"Shang Y, Jin Y, Liu H, Ding L, Tong X, Tu H, Zang L, Lin C, Hu J, Zhou F (2022) Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. Hematol Oncol 40(2):212\u2013222. https:\/\/doi.org\/10.1002\/hon.2955","journal-title":"Hematol Oncol"},{"issue":"1","key":"6630_CR84","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK (2022) A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J 12(1):21. https:\/\/doi.org\/10.1038\/s41408-022-00611-x","journal-title":"Blood Cancer J"},{"issue":"Suppl 2","key":"6630_CR85","first-page":"66","volume":"52","author":"P Fabian","year":"2006","unstructured":"Fabian P, Moulis M (2006) Moznosti histologick\u00e9ho Vysetren\u00ed Kostn\u00ed Drene Pri diagnostice Mnohocetn\u00e9ho myelomu [Options for histological examination of bone marrow during diagnosis of multiple myeloma]. Vnitr Lek 52(Suppl 2):66\u201370 Czech","journal-title":"Vnitr Lek"},{"issue":"1","key":"6630_CR86","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","volume":"148","author":"E P\u00e9rez-Persona","year":"2010","unstructured":"P\u00e9rez-Persona E, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Las Heras N, de Coca AG, Hern\u00e1ndez JM, Galende J, Mart\u00edn-Nu\u00f1ez G, B\u00e1rez A, Alonso JM, Mart\u00edn A, L\u00f3pez-Berges C, Orfao A, San Miguel JF, Vidriales MB (2010) Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 148(1):110\u2013114. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07929.x","journal-title":"Br J Haematol"},{"issue":"8","key":"6630_CR87","first-page":"1147","volume":"90","author":"A Wei","year":"2005","unstructured":"Wei A, Westerman D, Feleppa F, Trivett M, Juneja S (2005) Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 90(8):1147\u20131149","journal-title":"Haematologica"},{"issue":"8","key":"6630_CR88","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/10245332.2017.1309493","volume":"22","author":"J Qian","year":"2017","unstructured":"Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, Meng H (2017) Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. Hematology 22(8):472\u2013476. https:\/\/doi.org\/10.1080\/10245332.2017.1309493","journal-title":"Hematology"},{"issue":"9","key":"6630_CR89","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","volume":"20","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, Dispenzieri A, Kapoor P, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Kyle RA, Rajkumar SV, Kumar SK (2020) Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma Leuk 20(9):596\u2013601. https:\/\/doi.org\/10.1016\/j.clml.2020.03.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6630_CR90","doi-asserted-by":"publisher","first-page":"101910","DOI":"10.1016\/j.eclinm.2023.101910","volume":"58","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A (2023) SLiM CRAB criteria revisited: Temporal trends in prognosis of patients with smoldering multiple myeloma who Meet the definition of \u2018biomarker-defined early multiple myeloma\u2019-a systematic review with meta-analysis. EClinicalMedicine 58:101910. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101910","journal-title":"EClinicalMedicine"},{"key":"6630_CR91","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231222477","volume":"30","author":"M Carlisi","year":"2024","unstructured":"Carlisi M, Presti RL, Mancuso S, Siragusa S, Caimi G (2024) Thrombotic risk and calculated whole blood viscosity in a cohort of patients with new diagnosis of multiple myeloma. Clin Appl Thromb Hemost 30:10760296231222477. https:\/\/doi.org\/10.1177\/10760296231222477","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"6630_CR92","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1038\/s41598-024-53385-6","volume":"14","author":"M Carlisi","year":"2024","unstructured":"Carlisi M, Presti RL, Plano F, Mancuso S, Siragusa S, Caimi G (2024) Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma. Sci Rep 14(1):2832. https:\/\/doi.org\/10.1038\/s41598-024-53385-6","journal-title":"Sci Rep"},{"issue":"6","key":"6630_CR93","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1172\/JCI114392","volume":"84","author":"R Bataille","year":"1989","unstructured":"Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84(6):2008\u20132011. https:\/\/doi.org\/10.1172\/JCI114392","journal-title":"J Clin Invest"},{"issue":"3","key":"6630_CR94","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archinte.1990.00390150095018","volume":"150","author":"YH Chen","year":"1990","unstructured":"Chen YH, Magalhaes MC (1990) Hypoalbuminemia in patients with multiple myeloma. Arch Intern Med 150(3):605\u2013610","journal-title":"Arch Intern Med"},{"issue":"10","key":"6630_CR95","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/cncr.11072","volume":"97","author":"VM Lauta","year":"2003","unstructured":"Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97(10):2440\u20132452. https:\/\/doi.org\/10.1002\/cncr.11072","journal-title":"Cancer"},{"issue":"4","key":"6630_CR96","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00277-009-0841-4","volume":"89","author":"JE Kim","year":"2010","unstructured":"Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C (2010) Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol 89(4):391\u2013397. https:\/\/doi.org\/10.1007\/s00277-009-0841-4Epub 2009 Oct 21","journal-title":"Ann Hematol"},{"issue":"7","key":"6630_CR97","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/10245332.2015.1101969","volume":"21","author":"YK Chen","year":"2016","unstructured":"Chen YK, Han SM, Yang Y, Lin TH, Tzeng HE, Chang KH, Hwang WL, Teng CL (2016) Early mortality in multiple myeloma: experiences from a single institution. Hematology 21(7):392\u2013398. https:\/\/doi.org\/10.1080\/10245332.2015.1101969","journal-title":"Hematology"},{"issue":"5","key":"6630_CR98","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bjh.18324","volume":"198","author":"Z McQuilten","year":"2022","unstructured":"McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A, Australian and New Zealand Myeloma and Related Diseases Registry (2022) Predictors of early mortality in multiple myeloma: results from the Australian and New Zealand myeloma and related diseases registry (MRDR). Br J Haematol 198(5):830\u2013837. https:\/\/doi.org\/10.1111\/bjh.18324","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06630-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:22Z","timestamp":1764729082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06630-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":98,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6630"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06630-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University Hospital of Palermo (report N\u00b0 01\/2022). Informed consent was obtained from all of the enrolled subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}